Jul. 7, 2014
Yabao Pharmaceutical announced on July 7, 2014 that it has entered into a strategic partnership with Eli Lilly to co-develop Lilly's leading glucokinase activator (GKA), LY2608204. Lilly's GKA has completed Phase 1 studies in the US in addition to extensive pre-clinical development.
Under the terms of the agreement, Yabao receives rights to develop and commercialize the GKA compound in China while Lilly retains rights in all other markets. The parties will collaborate to determine a strategic development plan for China and Yabao will initially be responsible to perform and fund all development, with Lilly having future buy-in options for China. Financial terms were not disclosed.